MKMerck KGaASee all their emails
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
A real announcement email from Merck KGaA. Captured May 21, 2026.
Make this email yours
Migma AI designs one like it with your logo, colors, and images.
About this email
Captured Announcement
Merck announces the first patient dosed in a Phase 3 clinical trial for a new colorectal cancer treatment.
The email features a branded header with the Merck logo, followed by a blue hero section containing the headline and a portrait image. The body is a clean, single-column layout focused on text, with clear section headers and bullet points for readability.
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.